Element Capital Management’s Antares Pharma, Inc. ATRS Stock Holding History

Element Capital Management’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-14,453	Closed	-$32K	–	1068
2018 Q1	$32K	Buy	+14,453	New	+$32.5K	﹤0.01%	800
2017 Q2	–	Sell	-12,347	Closed	-$35K	–	148
2017 Q1	$35K	Buy	+12,347	New	+$29.7K	0.01%	24

Other funds holding ATRS

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MWP

MYCIO Wealth Partners Philadelphia, Pennsylvania $502M AUM 11.65% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Element Capital Management's ATRS Position: Q2 2018 in Review

Element Capital Management sold out of Antares Pharma, Inc. (ATRS) in Q2 2018, closing a stake of 14,453 shares — an estimated $32K sold.

Element Capital Management first reported a position in ATRS in Q1 2017 and held it in 2 quarters. The position peaked at $35K in Q1 2017. 101 funds tracked by Wall St. Rank hold ATRS as of Q2 2018.

Element Capital Management reported no remaining Antares Pharma, Inc. position as of Q2 2018 after selling out during the quarter.
Element Capital Management sold 14,453 Antares Pharma, Inc. shares in Q2 2018, an estimated $32K.
Element Capital Management first reported a position in Antares Pharma, Inc. in Q1 2017 and held it in 2 quarters.
Element Capital Management's Antares Pharma, Inc. position peaked at $35K in Q1 2017.
101 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2018.

Based on Element Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.